U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625332) titled 'Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)' on May 19.
Brief Summary: The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Spinal Cord Injury
Traumatic Spinal Cord Injury
Paraplegia an...